Search
Now showing items 11-17 of 17
Pramipexole Enhances Reward Learning by Preserving Value Estimates
(2022-01)
Background: Dopamine D2-like receptor agonists show promise as treatments for depression. They are
thought to act by altering how individuals learn from rewarding experiences. However, the nature of these
reward learning ...
Accuracy in recognising happy facial expressions is associated with antidepressant response to a NOP receptor antagonist but not placebo treatment
(2021-10)
Background: Clinical trials with putative antidepressants can be difficult to execute as it can take up to 8 weeks before differences emerge between drug and placebo, and long expensive trials often fail. Implementation ...
Characterizing Affective Variability in Bipolar Disorder and Borderline Personality Disorder, and the Effects of Lithium, Using a Generative Model of Affect
(2022-02)
The affective variability of Bipolar Disorder (BD) is thought to qualitatively differ from that of Borderline Personality Disorder (BPD), with changes in affect persisting for longer in BD. However, quantitative studies ...
Brain activity measured by functional brain imaging predicts breathlessness improvement during pulmonary rehabilitation
(2022-12)
Background Chronic breathlessness in chronic obstructive pulmonary disease (COPD) is effectively treated with pulmonary rehabilitation. However, baseline patient characteristics predicting improvements in breathlessness ...
Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy
(2023-08)
Ulotaront, a trace amine-associated receptor 1 (TAAR1) and serotonin 5-HT1A receptor agonist without antagonist activity at dopamine D2 or the serotonin 5-HT2A receptors, has demonstrated efficacy in the treatment of ...
Pro-dopaminergic pharmacological interventions for anhedonia in depression: protocol for a living systematic review of human and non-human studies
(2023-10)
Anhedonia is a key symptom of depression, and it has been suggested as a potential target for future individualised treatments. However, much is unknown about how interventions enhancing dopaminergic pathways may affect ...
Cognitive Remediation in Bipolar (CRiB2): study protocol for a randomised controlled trial assessing efficacy and mechanisms of cognitive remediation therapy compared to treatment as usual
(2023-11)
A substantial proportion of people with bipolar disorder (BD) experience persistent cognitive difficulties associated with impairments in psychosocial functioning and a poorer disorder course. Emerging evidence suggests ...